Lyell Immunopharma (LYEL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting commenced at 8:00 A.M. Pacific on June 10, 2026, via a virtual platform, with introductions of the Board, executive team, and key advisors.
The agenda included three proposals: election of directors, ratification of auditors, and an advisory vote on executive compensation.
Board and executive committee updates
Board members and executive team were introduced, including roles such as CEO, CFO, COO, General Counsel, and Chief Scientific Officer.
Shareholder proposals
No stockholder nominations for director positions were submitted in advance as required by bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lyell Immunopharma
- Ronde-cel’s high response rates and durability underpin pivotal trials and a planned 2027 BLA submission.LYEL
Stifel 2026 Healthcare Conference 2026 - Ronde-cel pairs high response rates with a head-to-head phase III and a 2027 filing target.LYELGoldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q
- Ronde-cel trials advanced as an $80M placement was expected to extend runway into 2028.LYELQ3 2026
- $562.7M cash runway into 2027 supports multiple 2024 clinical milestones.LYELQ4 2023
- Strong clinical progress in CAR T-cell therapies with pivotal data and regulatory milestones ahead.LYEL2026 Global Healthcare Conference
- Pivotal CAR T-cell therapies show strong efficacy, safety, and commercial readiness for major cancer markets.LYELCompany presentation
- Pivotal CAR T-cell trials advanced with $228M cash reserves and a Q2 net loss of $44.8M.LYELQ2 2026
- 1,100,000 shares registered for ICT Holdings' resale as part of a strategic licensing deal.LYELRegistration filing
- Pivotal cell therapy trials show strong efficacy, with major data and regulatory milestones ahead.LYELH.C. Wainwright 4th Annual Cell Therapy Virtual Conference